News | July 18, 2021
Veeda Clinical Research acquires majority stake in Bioneeds
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Oxygen Park is a concept where a two-layer layout is being used to plant oxygen releasing trees which releases oxygen for 24 hours
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
